Skip to content

COMBINATIONS

DRUG19 trials

Sponsors

Region Oestergoetland, Merck Sharp & Dohme LLC, Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd., ACO Hud Nordic AB, Novartis Pharma AG

Conditions

Advanced or Metastatic Non-small Cell Lung CancerAtopic dermatitisColorectal CancerColorectal cancer with metastasisDrug-Related Side Effects and Adverse ReactionsEpendymomaEpendymoma MalignantEpendymoma of Brain

Phase 1

Phase 2

Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer
CompletedNCT05414461
First Affiliated Hospital of Zhejiang UniversityColorectal Cancer
Start: 2019-03-10End: 2022-04-30Updated: 2022-06-10
A randomised controlled trial of a moisturiser for treatment of dry skin in atopic dermatitis: effect on the skin barrier in adults with a history of eczema
CompletedCTIS2023-508560-29-00
ACO Hud Nordic ABAtopic dermatitis
Start: 2023-12-07End: 2024-03-14Target: 55Updated: 2024-04-15
OPTIMISE OPTIMIzation of treatment SElection and follow up in oligometastatic colorectal cancer – a ctDNA guided phase II randomized approach
RecruitingCTIS2023-509814-12-00
Region MidtjyllandColorectal cancer with metastasis
Start: 2021-09-22Target: 381Updated: 2026-01-20
An open-label, non-randomized, biopsy-based mechanistic study on pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome
CompletedCTIS2023-508957-24-00
Novartis Pharma AGSjögren's syndrome
Start: 2022-07-27End: 2026-01-05Target: 20Updated: 2025-04-29
A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory colorectal cancer patients (TROPHIT1)
Active, not recruitingCTIS2023-509771-17-00
Universitaetsklinikum Heidelberg AöRMetastatic Colorectal cancer (mCRC)
Start: 2024-06-04Target: 80Updated: 2025-01-21
A Phase II Study of SKB264 as Monotherapy or as Combination Therapy in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer
Active, not recruitingCTIS2023-507270-41-00
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.Advanced or Metastatic Non-small Cell Lung Cancer
Start: 2024-11-22Target: 46Updated: 2025-07-29
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable /Metastatic Solid Tumors Who are Refractory to Available Standard Therapies
CompletedCTIS2023-508700-38-00
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.Metastatic or locally advanced unresectable solid tumors progressing after available standard therapies
End: 2024-12-10Target: 31Updated: 2024-06-20
BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, multicenter, comparative, randomized GERCOR G-124 BETWEEN phase II study
Not yet recruitingCTIS2024-520128-27-00
Association Gercorcolorectal adenocarcinoma
Target: 162Updated: 2025-10-20
J2R-MC-YAAD: A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease
Not yet recruitingCTIS2025-522204-24-00
Eli Lilly & Co.Drug-Related Side Effects and Adverse Reactions, Nausea, Neoplasms +1
Target: 15Updated: 2026-02-23

Phase 3

Does adding patient-controlled sedation with propofol during repair of obstetric perineal lacerations grade I and II improve patient experiences - a randomized control trial
RecruitingCTIS2022-502292-39-00
Region OestergoetlandObstetric perineal lacerations
Start: 2023-09-19Target: 80Updated: 2023-03-29
A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer (KEYFORM-007)
CompletedCTIS2024-511043-25-00
Merck Sharp & Dohme LLCColorectal Cancer
Start: 2021-11-30End: 2025-02-21Target: 102Updated: 2025-02-04
A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
RecruitingCTIS2023-505423-31-00
Merck Sharp & Dohme LLCadvanced or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma
Start: 2024-08-08Target: 115Updated: 2025-08-20
A phase III, international, multiCenter, randomized, paraLlel-group, Endoscopist-blinded non-inferiority study of the efficAcy, safety and patient acceptance of mannitol veRsus Plenvu® in boWel prepAration for elective colonoscopY. CLEARWAY
RecruitingCTIS2025-521451-23-00
Ntc S.r.l.Subjects scheduled for elective colonoscopy performed according to ESGE (European Society of Gastrointestinal Endoscopy) guidelines.
Start: 2025-09-03Target: 520Updated: 2025-12-12

Phase 4

Unknown Phase

Related Papers